A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Status:
Completed
Trial end date:
2018-10-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in
patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv
in ALS (CY 4031).